Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer

DISEASE CHARACTERISTICS: * Histologically confirmed endometrial cancer, including any 1 of the following subtypes: * Adenocarcinoma * Papillary serous * Papillary * Villoglandular * Mucinous * Clear cell * Endometrioid * Adenosquamous carcinoma * Recurrent or metastatic and/or locally advanced disease * Incurable disease by standard therapies * Clinically and/or radiologically documented disease within the past 28 days (35 days if negative), defined as ≥ 1 unidimensionally measurable disease site meeting 1 of the following criteria: * At least 20 mm by x-ray or physical exam * At least 10 mm by spiral CT scan * At least 20 mm by non-spiral CT scan * Available tumor tissue (paraffin block or unstained slides) from primary tumor * No uterine sarcoma (leiomyosarcoma), mixed müllerian tumor (MMT), and/or adenosarcoma * No known brain metastases * Clinical suspicion of CNS involvement requires a head CT scan PATIENT CHARACTERISTICS: * ECOG performance status 0-2 * Life expectancy ≥ 12 weeks * Granulocyte count ≥ 1,500/mm³ * Platelet count ≥ 100,000/mm³ * Bilirubin ≤ upper limit of normal (ULN) * ALT and AST ≤ 2.5 times ULN * Creatinine ≤ 1.25 times ULN OR creatinine clearance ≥ 50 mL/min * Fasting serum cholesterol ≤ 9.0 mmol/L * Fasting triglycerides ≤ 4.56 mmol/L * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Accessible for treatment and follow up (e.g., 1 ½ hours driving distance from participating center) * No upper gastrointestinal or other condition that would impair swallowing or absorption of oral medication * No serious illness or medical condition that would not permit the patient to be managed according to the protocol, including, but not limited to, any of the following: * History of significant neurologic or psychiatric disorder (e.g., uncontrolled psychotic disorders) that would impair the ability to obtain consent or limit compliance with study requirements * Active uncontrolled or serious infection * Active peptic ulcer disease * Myocardial infarction within the past 6 months, congestive heart failure (even if medically controlled), unstable angina, active cardiomyopathy, unstable ventricular arrhythmia, or uncontrolled hypertension * Pulmonary disease requiring oxygen * HIV infection or other immune deficiency * Other medical conditions that might be aggravated by study treatment * No history of other malignancies, except adequately treated nonmelanoma skin cancer, curatively treated carcinoma in situ of the cervix, or other solid tumors curatively treated with no evidence of disease for ≥ 5 years * No known hypersensitivity to the study drug or its components PRIOR CONCURRENT THERAPY: * At least 7 days since prior hormonal therapy (progestational or aromatase inhibitor) as either adjuvant therapy or for treatment of metastatic disease * At least 21 days since prior major surgery and recovered * At least 28 days since prior radiotherapy and recovered * Prior low-dose palliative radiotherapy allowed * At least 4 months since prior adjuvant chemotherapy * No prior mTOR inhibitors * No prior or concurrent chemotherapy for metastatic or recurrent disease * More than 7 days since prior and no concurrent CYP3A4 inhibitors including, but not limited to, any of the following: * Azole antifungals (i.e., ketoconazole, itraconazole, miconazole, fluconazole) * HIV protease inhibitors (i.e., indinavir, saquinavir, ritonavir, atazanavir, nelfinavir) * Clarithromycin * Verapamil * Erythromycin * Delavirdine * Diltiazem * Nefazodone * Telithromycin * More than 12 days since prior and no concurrent CYP3A4 inducers including, but not limited to, any of the following: * Rifampin * Phenytoin * Rifabutin * St. John's wort * Carbamazepine * Efavirenz * Phenobarbital * Tipranavir * At least 14 days since prior and no concurrent investigational drugs or anticancer therapy (e.g., immunotherapy, biological response modifiers \[excluding hematopoietic growth factors\], and systemic hormonal therapy) * No concurrent CYP3A4 substrates